Actively Recruiting
Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Led by Charles University, Czech Republic · Updated on 2024-08-27
50
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
Sponsors
C
Charles University, Czech Republic
Lead Sponsor
F
Faculty Hospital Kralovske Vinohrady
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early. Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect
CONDITIONS
Official Title
Topical Sevoflurane for Treatment of Chronic Leg Ulcers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS>4) non- healing tibial venous ulcers
You will not qualify if you...
- Allergy to sevoflurane
- Inability to understand the pain-intensity questionnaire
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty Hospital Kralovske Vinohrady
Prague, Czechia, 100 00
Actively Recruiting
Research Team
J
Jiri Malek, M.D.
CONTACT
J
Jiri Malek, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here